A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B-

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03114865` - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance	Phase 1/Phase 2
Recruiting	`NCT04836195` - Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma	Phase 1
Active, not recruiting	`NCT04088890` - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	Phase 1
Recruiting	`NCT05472558` - Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL	Phase 1
Recruiting	`NCT04191941` - Treatment of Hematological Malignancy With Novel CAR-T Cells.	Early Phase 1
Active, not recruiting	`NCT04148430` - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy	Phase 2
Recruiting	`NCT05702853` - Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL	Phase 1/Phase 2
Not yet recruiting	`NCT05991388` - A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma	Phase 2/Phase 3
Recruiting	`NCT04887012` - Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL	Phase 1
Completed	`NCT04030195` - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	Phase 1/Phase 2
Recruiting	`NCT04594642` - A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT05338931` - Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05164770` - Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma	Phase 3
Completed	`NCT05260203` - MargheRITA (Remote Intelligence for Therapeutic Adherence)	N/A
Active, not recruiting	`NCT05094206` - CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies	Phase 1
Recruiting	`NCT06392477` - A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1
Completed	`NCT04748185` - Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Active, not recruiting	`NCT03283137` - Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL	Phase 1
Completed	`NCT02910063` - Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL	Phase 2/Phase 3
Recruiting	`NCT05744037` - Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells	Phase 2

NCT number	NCT04412174
Study type	Interventional
Source	Hebei Yanda Ludaopei Hospital
Contact	Peihua Lu, PhD&MD
Phone	+86-0316-3306393
Email	Peihua_lu@126.com
Status	Not yet recruiting
Phase	Early Phase 1
Start date	June 2020
Completion date	December 2022

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms